极光加速器2025官网

极光加速器2025官网

iphone浏览国外网站™ is a development stage, regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders.


Our first product, ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis. 

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Dec. 14, 2018 — Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”

Read More

Vision Statement

To provide patients suffering with IBD, and other diseases of the lower GI and urogenital tract, regenerative medicine treatments for their disease, to improve their quality of life.

Mission Statement

We are a development stage regenerative medicine company whose mission is to develop novel applications of extracellular matrix to treat IBD and put patients suffering with the disease into deep remission.

番茄加速器7天试用,番茄加速器用不了了,番茄加速器2025年,番茄加速器vps  蚯蚓加速器免费试用,蚯蚓加速器2025,蚯蚓加速器vp,蚯蚓加速器vps  西部世界梯子官网网址,西部世界梯子用不了了,西部世界梯子2025年,西部世界梯子vp  自由浏览2025最新版下载  佛跳墙vp最新版2025极光 mac  极光aurora加速器2025官网